Peter jinwoo Shin1, Zihan Zhu1, Roman Camarda2, Robert Bok1, Alicia Zhou2, Andrei Goga2, and Daniel B Vigneron1
1Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, 2Biomedical Science Program, University of California, San Francisco, San Francisco, CA, United States
Synopsis
We used hyperpolarized [1-13C]pyruvate imaging to monitor tumor progression
and regression in a murine breast cancer model that conditionally expresses the
human c-MYC transgene in a
doxycycline switchable manner. Previously, it was shown that this model could
develop a secondary tumor even after the primary tumor regresses nearly fully following
c-MYC deinduction. Hence, the purpose of this project was to
monitor altered glycolytic metabolism by hyperpolarized metabolic MRI in this
multi-stage mammary tumorigenesis animal model.Purpose
The lactate dehydrogenase-A gene (
LDH-A), whose product catalyzes the inter-conversion of pyruvate and lactate, is a known
c-MYC-responsive gene
1. We
used hyperpolarized [1-
13C]pyruvate imaging to
monitor tumor progression and regression in a murine breast cancer model that conditionally
expresses the human
c-MYC transgene
in a doxycycline switchable manner. Previously, it was shown that this model could
develop a secondary tumor even after the primary tumor regresses nearly fully following
c-MYC deinduction
2. Hence, the purpose of this project was to
monitor altered glycolytic metabolism by hyperpolarized metabolic MRI in this
multi-stage mammary tumorigenesis animal model.
Methods
Tumor grafts derived from a human
c-MYC transgenic mouse were transplanted
into one of the mammary glands of normal female FVB mice. Following the
transplant, the mice were fed with chows containing doxycycline (doxy-chow) for
deregulated c-MYC expression from the onset. After the formation of palpable
tumors, we performed a baseline [1-
13C]pyruvate imaging study and
removed the doxy-chow from the diet (off-doxy) for tumor regression. In the
span of 7 weeks, follow up studies were performed at multiple time points (4,
16, 33, 49 days after the baseline).
1H images were also acquired to
monitor morphological changes and to spatially register the
13C
data. Changes in tumor volume over time were measured from the proton images.
Results
1) Morphological
regression of the tumor (50% decrease in volume from the baseline) was observed
as soon as 4 days after off-doxy (c-MYC deinduction) together with a 80% decreased
lactate-to-pyruvate ratio (Figure 1). Lactate production further decreased
until the 16
th day as shown in the
13C spectra and the
lac/pyr image. Then, on the 33
rd day after off-doxy, an increase in
the lactate-to-pyruvate ratio was observed, eventhough there were no apparent
changes in the tumor volume at this point. Subsequently, a recurrent solid
tumor mass was observed after 49 days post off-doxy with dramatically increased
lactate production.
2) From a different animal, we observed a possible metastatic lesion
forming in the mouse liver (44 days post off-doxy) together with a recurrent
tumor in its primary tumor site (Figure 2). The
13C data showed high levels of alanine
production only in the liver voxels.
Discussion
1) An increase in lactate-to-pyruvate
ratio as measured by hyperpolarized [1-
13C]pyruvate imaging was
observed weeks before the formation of a secondary tumor, which recurred in a
doxycycline independent manner. This observation suggets that when
there is a secondary genetic mutation, of which
LDH-A is a downstream target, then hyperpolarized metabolic MRI can detect the tumor
recurrence much faster than conventional
1H anatomical imaging.
2) Previously, a high rate of conversion from pyruvate to
alanine has been observed in pre-tumor stage of c-MYC-induced liver cancer mice
3. Our data suggests that hyperpolarized [1-
13C]pyruvate imaging is capable
of detecting possible liver metastasis even when conventional
1H anatomical imaging fails to
reveal the pathogenic lesions.
Conclusion
We observed that hyperpolarized [1-
13C]pyruvate metabolic imaging could detect the
in vivo glycolytic alterations that occur
following
c-MYC transgene
induction/deinduction at different stages of mammary tumor formation.
Acknowledgements
This project is funded by NIH P41EB013598 grant.References
1. Shim H, et al..
C-Myc transactivation of LDH-A: implications for tumor metabolism and
growth. Proc Natl Acad Sci USA. 1997;94(13):6658-6663.
2. D’Cruz CM, et al..
c-MYC induces mammary tumorigenesis by means of a preferred pathway
involving spontaneous Kras2 mutations. Nat Med. 2001;7:235-239.
3. Hu S, et al..
13C-Pyruvate Imaging Reveals Alterations in Glycolysis that Precede
c-Myc-Induced Tumor Formation and Regression. Cell Met. 2011;14:131-142.